MYB promoted leukemia stem cell phenotype via interaction with the insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), and IGF2BP1 knockdown sensitized leukemia cells to the DNA-targeting drugs doxorubicin, cyclophosphamide, and cytarabine. The gene discussed is MYB; the disease is leukemia.